Jorge-Shmuel Delgado1, Yael Baumfeld2, Victor Novack2, Shulamit Monitin3, Alan Jotkowitz3,4, Ohad Etzion2, Alexander Fich2. 1. Department of Gastroenterology and Hepatology, Faculty of Health Sciences, The Barzilai Medical Centre, Ben-Gurion University of the Negev, Beersheba, Israel. delgado@bgu.ac.il. 2. Faculty of Health Sciences, Clinical Research Centre, Soroka University Medical Centre, Ben-Gurion University of the Negev, Beersheba, Israel. 3. Department of Gastroenterology and Hepatology, Faculty of Health Sciences, Soroka University Medical Centre, Ben-Gurion University of the Negev, Beersheba, Israel. 4. Department of Internal Medicine, Faculty of Health Sciences, Soroka University Medical Centre, Ben-Gurion University of the Negev, Beersheba, Israel.
Abstract
BACKGROUND AND PURPOSE: The efficacy and safety of pegylated interferon and ribavirin treatment for chronic hepatitis C (CHC) in the Jewish population has not been previously ascertained. The aims of our study were to determine the efficacy of pegylated interferon and ribavirin therapy in an Israeli outpatient practice. METHODS: The medical records of 331 consecutive naïve patients with CHC infection treated with pegylated interferon and ribavirin between 2003 and 2010 were reviewed in order to document the virological response to the combination therapy. We used logistic regression to identify predictors for the sustained virological response (SVR). Variable selection in multivariable modeling was based on clinical and statistical significance and performed in a hierarchical fashion. First demographic characteristics, then patient clinical characteristics, viral characteristics, and finally adherence to the therapy were introduced into the model. RESULTS: The overall SVR was 57.1% (42.5% in genotype 1, 87.5% in genotype 2, 81.6% in genotype 3, and 100% in genotype 4). SVR was significantly associated with genotype 2 (OR 3.77, 95% CI 1.04-13.60, P = 0.04), genotype 3 (OR 9.72, 95% CI 4.07-23.20, P < 0.001), baseline viral load lower than 400,000 IU/mL (OR 23.1, 95% CI 8.23-64.98, P < 0.001), and adherence to the 80/80/80 rule (OR 36.22, 95% CI 11.14-117.72, P < 0.001). CONCLUSIONS: Combined pegylated interferon and ribavirin therapy was of similar or even higher efficacy in the Israeli population as compared to that reported by international trials in Caucasian, Hispanic, and African American populations.
BACKGROUND AND PURPOSE: The efficacy and safety of pegylated interferon and ribavirin treatment for chronic hepatitis C (CHC) in the Jewish population has not been previously ascertained. The aims of our study were to determine the efficacy of pegylated interferon and ribavirin therapy in an Israeli outpatient practice. METHODS: The medical records of 331 consecutive naïve patients with CHC infection treated with pegylated interferon and ribavirin between 2003 and 2010 were reviewed in order to document the virological response to the combination therapy. We used logistic regression to identify predictors for the sustained virological response (SVR). Variable selection in multivariable modeling was based on clinical and statistical significance and performed in a hierarchical fashion. First demographic characteristics, then patient clinical characteristics, viral characteristics, and finally adherence to the therapy were introduced into the model. RESULTS: The overall SVR was 57.1% (42.5% in genotype 1, 87.5% in genotype 2, 81.6% in genotype 3, and 100% in genotype 4). SVR was significantly associated with genotype 2 (OR 3.77, 95% CI 1.04-13.60, P = 0.04), genotype 3 (OR 9.72, 95% CI 4.07-23.20, P < 0.001), baseline viral load lower than 400,000 IU/mL (OR 23.1, 95% CI 8.23-64.98, P < 0.001), and adherence to the 80/80/80 rule (OR 36.22, 95% CI 11.14-117.72, P < 0.001). CONCLUSIONS: Combined pegylated interferon and ribavirin therapy was of similar or even higher efficacy in the Israeli population as compared to that reported by international trials in Caucasian, Hispanic, and African American populations.
Authors: G Borroni; M Andreoletti; M A Casiraghi; R Ceriani; P Guerzoni; B Omazzi; N Terreni; F Salerno Journal: Aliment Pharmacol Ther Date: 2008-02-21 Impact factor: 8.171
Authors: Wendy S C Cheng; Stuart K Roberts; Geoffrey McCaughan; William Sievert; Martin Weltman; Darrell Crawford; William Rawlinson; Philippa S Marks; James Thommes; Bishoy Rizkalla; Motoko Yoshihara; Gregory J Dore Journal: J Hepatol Date: 2010-06-16 Impact factor: 25.083
Authors: M Soresi; S Tripi; V Franco; L Giannitrapani; A Alessandri; F Rappa; O Vuturo; G Montalto Journal: Liver Int Date: 2006-11 Impact factor: 5.828
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Thomas M Shehab; Robert J Fontana; Kelly Oberhelman; Jorge A Marrero; Grace L Su; Anna S F Lok Journal: Clin Gastroenterol Hepatol Date: 2004-05 Impact factor: 11.382
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Paul Feuerstadt; Ari L Bunim; Heriberto Garcia; Jordan J Karlitz; Hatef Massoumi; Amar J Thosani; Andrew Pellecchia; Allan W Wolkoff; Paul J Gaglio; John F Reinus Journal: Hepatology Date: 2010-04 Impact factor: 17.425